In vivo upregulation of endogenous NGF in the rat brain by the alpha2-adrenoreceptor antagonist dexefaroxan: potential role in the protection of the basalocortical cholinergic system during neurodegeneration.
We have previously reported that the alpha2-adrenoceptor antagonist dexefaroxan protects against the degeneration of nucleus basalis magnocellularis (NbM) cholinergic neurons following cortical devascularization in the adult rat. Since nerve growth factor (NGF) is critical to the survival of NbM cholinergic neurons in the adult brain and its synthesis is known to be regulated by noradrenergic mechanisms, we examined whether the protective effect of dexefaroxan in the devascularization model was associated with regional induction of NGF biosynthesis. Dexefaroxan or vehicle was administered to rats via subcutaneous minipumps for 28 days following devascularization or sham operation procedures. In vehicle-treated devascularized rats, NGF protein levels in the cortex were increased at 5 days but had normalized by 2 weeks postoperation; NGF levels in NbM remained unchanged during this time. In dexefaroxan-treated devascularized rats, increases in NGF protein levels (2-fold) and immunoreactivity were maintained in both the cortex and NbM over the entire 28-day postoperation period; these increases were coincident with changes in functional markers characteristic of NGF's actions, including increases in choline acetyltransferase (ChAT), p75 and TrkA immunoreactivities, and a preservation of NbM cholinergic cell numbers. Dexefaroxan also increased NGF protein levels in sham-operated rats, but without any significant consequence to the otherwise normal NbM cholinergic phenotype in these animals. Results indicate that activation of endogenous NGF systems could contribute to the cholinergic protective effect of dexefaroxan in the cortical devascularization model, and provide further support for a potential therapeutic utility of dexefaroxan in neurodegenerative diseases where central cholinergic function is progressively compromised.
Debeir
Thomas
T
INSERM U289, Neurologie et Thérapeutique Expérimentale, Hôpital de la Salpêtrière, Paris, France. tdebeir@ccr.jussieu.fr
Marien
M
M
Ferrario
J
J
Rizk
P
P
Prigent
A
A
Colpaert
F
F
Raisman-Vozari
R
R
D000109:Acetylcholine / Q000378:metabolism; D058669:Adrenergic alpha-2 Receptor Antagonists; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D002545:Brain Ischemia / Q000473:pathology / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D007093:Imidazoles / Q000494:pharmacology*; D007150:Immunohistochemistry; D009410:Nerve Degeneration / Q000188:drug therapy*; D020932:Nerve Growth Factor / Q000187:drug effects* / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D013003:Somatosensory Cortex / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D015854:Up-Regulation
D058669:Adrenergic alpha-2 Receptor Antagonists; D001578:Benzopyrans; D007093:Imidazoles; D018696:Neuroprotective Agents; D020932:Nerve Growth Factor; C451723:dexefaroxan; D000109:Acetylcholine